Company Overview of Lux Biosciences, Inc.
Lux Biosciences, Inc., a biotechnology company, engages in the development and commercialization of medications for ophthalmic diseases in the United States and internationally. Its products comprise LUVENIQ, an oral form of calcineurin inhibitor voclosporin, which is used for the treatment of non-infectious uveitis; LX214, a topical formulation that contains mixed nanomicelles of voclosporin for ophthalmic use; LX212, a bioerodible polymer implant containing voclosporin; and LX213, a bioerodible/isotechnika implant. The company was incorporated in 2005 and is based in Jersey City, New Jersey.
3 Second Street
Harborside Financial Center Plaza 10
Jersey City, NJ 07302
Founded in 2005
Key Executives for Lux Biosciences, Inc.
Similar Private Companies By Industry
|Metabolic Solutions Development Company, LLC||United States|
|Phage International, Inc.||United States|
|Biomedical Development Corporation||United States|
|3D Biomatrix Inc.||United States|
|ImmuneWorks, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Lux Biosciences, Inc., please visit www.luxbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.